Αποτελέσματα Αναζήτησης
Conclusion: Further research is needed to correlate the increase in Hcy with specific symptoms/ deficits in ASD and to evaluate the clinical impact of strategies that can reduce Hcy concentration in ASD. Keywords: Autism spectrum disorder; biomarker; core symptoms; homocysteine; language development; metabolism..
- A focus on homocysteine in autism - PubMed
Therefore, monitoring of homocysteine levels in body fluids...
- A focus on homocysteine in autism - PubMed
26 Δεκ 2019 · Moreover, lower GSH levels in the GI tract can promote inflammation and contribute to symptoms of GI discomfort and dysfunction. Thus, a GFCF diet may provide clinical benefit by improving CYS absorption and GSH levels, particularly in individuals with low GSH levels, as is the case in ASD.
12 Σεπ 2013 · The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls. The current literature suffers from many methodological shortcomings which needed to be considered in future studies.
15 Αυγ 2022 · Our analyses demonstrated that children with severe ASD symptoms had a higher mean homocysteine level but a lower mean folate level than children with mild ASD symptoms, but no significant difference in serum vitamin B12 levels was observed between the two groups.
9 Ιουλ 2023 · In this review article, we summarize the main findings of nutritional studies in ASDs, with an emphasis on the most common monogenic cause of autism, Fragile X Syndrome (FXS), and the most studied dietary intervention, the ketogenic diet as well as other dietary interventions.
Therefore, monitoring of homocysteine levels in body fluids of autistic children can provide information on genetic and physiological diseases, improper lifestyle (including dietary habits), as well as a variety of pathological conditions.
14 Ιουν 2021 · Overview. This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
